The DOI matches its Crossref record; 608 of the 608 references it cites were found in a registry or an index.
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
Open accessAbstract
A recent explosion in the amount of cardiovascular risk and incipient, undetected subclinical cardiovascular pathology has swept across the globe. Nearly 70% of adult Americans are overweight or obese; the prevalence of visceral obesity stands at 53% and continues to rise. At any one time, 55% of the population is on a weight-loss diet, and almost all fail. Fewer than 15% of adults or children exercise sufficiently, and over 60% engage in no vigorous activity. Among adults, 11%-13% have diabetes, 34% have hypertension, 36% have prehypertension, 36% have prediabetes, 12% have both prediabetes and prehypertension, and 15% of the population with either diabetes, hypertension, or dyslipidemia are undiagnosed. About one-third of the adult population, and 80% of the obese, have fatty livers. With 34% of children overweight or obese, prevalence having doubled in just a few years, type 2 diabetes, hypertension, dyslipidemia, and fatty livers in children are at their highest levels ever. Half of adults have at least one cardiovascular risk factor. Not even 1% of the population attains ideal cardiovascular health. Despite falling coronary death rates for decades, coronary heart disease (CHD) death rates in US women 35 to 54 years of age may now be increasing because of the obesity epidemic. Up to 65% of patients do not have their conventional risk biomarkers under control. Only 30% of high risk patients with CHD achieve aggressive low density lipoprotein (LDL) targets. Of those patients with multiple risk factors, fewer than 10% have all of them adequately controlled. Even when patients are titrated to evidence-based targets, about 70% of cardiac events remain unaddressed. Undertreatment is also common. About two-thirds of high risk primary care patients are not taking needed medications for dyslipidemia. Poor patient adherence, typically below 50%, adds further difficulty. Hence, after all such fractional reductions are multiplied, only a modest portion of total cardiovascular risk burden is actually being eliminated, and the full potential of risk reduction remains unrealized. Worldwide the situation is similar, with the prevalence of metabolic syndrome approaching 50%. Primordial prevention, resulting from healthful lifestyle habits that do not permit the appearance of risk factors, is the preferred method to lower cardiovascular risk. Lowering the prevalence of obesity is the most urgent matter, and is pleiotropic since it affects blood pressure, lipid profiles, glucose metabolism, inflammation, and atherothrombotic disease progression. Physical activity also improves several risk factors, with the additional potential to lower heart rate. Given the current obstacles, success of primordial prevention remains uncertain. At the same time, the consequences of delay and inaction will inevitably be disastrous, and the sense of urgency mounts. Since most CHD events arise in a large subpopulation of low- to moderate-risk individuals, identifying a high proportion of those who will go on to develop events with accuracy remains unlikely. Without a refinement in risk prediction, the current model of targeting high-risk individuals for aggressive therapy may not succeed alone, especially given the rising burden of risk. Estimating cardiovascular risk over a period of 10 years, using scoring systems such as Framingham or SCORE, continues to enjoy widespread use and is recommended for all adults. Limitations in the former have been of concern, including the under- or over-estimation of risk in specific populations, a relatively short 10-year risk horizon, focus on myocardial infarction and CHD death, and exclusion of family history. Classification errors may occur in up to 37% of individuals, particularly women and the young. Several different scoring systems are discussed in this review. The use of lifetime risk is an important conceptual advance, since ≥90% of young adults with a low 10-year risk have a lifetime risk of ≥39%; over half of all American adults have a low 10-year risk but a high lifetime risk. At age 50 the absence of traditional risk factors is associated with extremely low lifetime risk and significantly greater longevity. Pathological and epidemiological data confirm that atherosclerosis begins in early childhood, and advances seamlessly and inexorably throughout life. Risk factors in childhood are similar to those in adults, and track between stages of life. When indicated, aggressive treatment should begin at the earliest indication, and be continued for years. For those patients at intermediate risk according to global risk scores, C-reactive protein (CRP), coronary artery calcium (CAC), and carotid intima-media thickness (CIMT) are available for further stratification. Using statins for primary prevention is recommended by guidelines, is prevalent, but remains underprescribed. Statin drugs are unrivaled, evidence-based, major weapons to lower cardiovascular risk. Even when low density lipoprotein choles
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 401–600 of 608
Krishna, R., Bergman, A., Jin, B., Fallon, M. S., Côté, J., Hoydonck, P. V., Laethem, T., Gendrano, I., Dyck, K. V., Hilliard, D., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.109 · Cited by 100
Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy
Hirayama, A., Saito, S., Ueda, Y., Takayama, T., Honye, J., Komatsu, S., Yamaguchi, O., Li, Y., Yajima, J., Nanto, S., et al. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-0755 · Cited by 97
Pearson, T. A., Blair, S. N., Daniels, S. R., Eckel, R. H., Fair, J. M., Fortmann, S. P., Franklin, B. A., Goldstein, L. B., Greenland, P., Grundy, S. M., et al. (2002) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 97
A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
Yamamoto, T., Lu, C., & Ryan, R. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199042 · Cited by 96
Goldberger, Z. D., Valle, J. A., Dandekar, V. K., Chan, P. S.-F., Ko, D. T., & Nallamothu, B. K. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.06.029 · Cited by 96
SHAH, A. S., Dolan, L. M., Kimball, T. R., Gao, Z., Khoury, P. R., Daniels, S. R., & Urbina, E. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2039 · Cited by 96
Modified HDL: Biological and physiopathological consequences
Norata, G. D., Pirillo, A., & Catapano, A. L. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.01.012 · Cited by 96
Signaling by the High-Affinity HDL Receptor Scavenger Receptor B Type I
Saddar, S., Mineo, C., & Shaul, P. W. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.196170 · Cited by 95
Insulin Resistance as a Proinflammatory State: Mechanisms, Mediators, and Therapeutic Interventions
Garg, R., Tripathy, D., & Dandona, P. (2003) · Current Drug Targets · doi:10.2174/1389450033490920 · Cited by 95
Cooper, A. M., & O’Flynn, N. (2008) · BMJ · doi:10.1136/bmj.39554.624086.ad · Cited by 93
Cannon, C. P., Dansky, H. M., Davidson, M. H., Gotto, A. M., Brinton, E. A., Gould, A. L., Stepanavage, M. E., Liu, S. X., Shah, S., Rubino, J., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.028 · Cited by 90
The Pediatric Obesity Epidemic Continues Unabated in Bogalusa, Louisiana
Broyles, S. T., Katzmarzyk, P. T., Srinivasan, S. R., Chen, W., Bouchard, C., Freedman, D. S., & Berenson, G. S. (2010) · PEDIATRICS · doi:10.1542/peds.2009-2748 · Cited by 89
Endoplasmic Reticulum Stress: Another Link Between Obesity and Insulin Resistance/Inflammation?
Boden, G. H. (2009) · Diabetes · doi:10.2337/db08-1746 · Cited by 89
Buchwald, H. (1992) · JAMA · doi:10.1001/jama.268.11.1429 · Cited by 87
Johnson, K. M., Dowe, D. A., & Brink, J. A. (2008) · American Journal of Roentgenology · doi:10.2214/ajr.08.1056 · Cited by 86
Ohashi, N., Yamamoto, H., Horiguchi, J., Kitagawa, T., Kunita, E., Utsunomiya, H., Oka, T., Kohno, N., & Kihara, Y. (2010) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2010.06.014 · Cited by 85
Imaging Vulnerable Plaque by Ultrasound
DeMaria, A. N., Narula, J., Mahmud, E., & Tsimikas, S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.047 · Cited by 84
Long‐term adherence to statin treatment in diabetes
Donnelly, L. A., Doney, A. S. F., Morris, A. D., Palmer, C. N. A., & Donnan, P. T. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02476.x · Cited by 84
Annual Progression of Coronary Calcification in Trials of Preventive Therapies: A Systematic Review
McCullough, P. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.382 · Cited by 82
Brewer, H. B., & Santamarina-Fojo, S. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03382-9 · Cited by 82
What Makes a Good Predictor?: The Evidence Applied to Coronary Artery Calcium Score
Ioannidis, J. P. A., & Tzoulaki, I. (2010) · JAMA · doi:10.1001/jama.2010.503 · Cited by 81
Coronary Mortality Declines in the U.S. Between 1980 and 2000
Young, F., Capewell, S., Ford, E. S., & Critchley, J. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2010.05.009 · Cited by 81
Diversity of Denizens of the Atherosclerotic Plaque
Libby, P., Nahrendorf, M., Pittet, M. J., & Świrski, F. K. (2008) · Circulation · doi:10.1161/circulationaha.108.783068 · Cited by 80
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00144 · Cited by 79
Storm over Statins — The Controversy Surrounding Pharmacologic Treatment of Children
de Ferranti, S. D., & Ludwig, D. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmp0805953 · Cited by 78
Obesity indicators and cardiometabolic status in 4-y-old children
Corvalán, C., Uauy, R. D., Kain, J., & Martorell, R. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27547 · Cited by 77
Boerwinkle, E., Chambless, L. E., Nambi, V., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/8pyz-rm95 · Cited by 77
Nabi, F., Chang, S. M., Pratt, C. M., Paranilam, J., Peterson, L. E., Frias, M. E., & Mahmarian, J. J. (2010) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2010.01.017 · Cited by 76
Capewell, S., Hayes, D., Ford, E. S., Critchley, J., Croft, J. B., Greenlund, K. J., & Labarthe, D. R. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp150 · Cited by 76
Cavanaugh-Hussey, M. W., Berry, J. D., & Lloyd‐Jones, D. M. (2008) · Preventive Medicine · doi:10.1016/j.ypmed.2008.07.012 · Cited by 75
Benefits of statin therapy and compliance in high risk cardiovascular patients
DEEDWANIA, P. C., & Lardizabal (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s9474 · Cited by 75
Perinatal and infant early atherosclerotic coronary lesions
Milei, J., Giulia Ottaviani, M., Lavezzi, A. M., Grana, D. R., Stella, I., & Matturri, L. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)70570-1 · Cited by 74
Early identification of cardiovascular risk using genomics and proteomics
Kullo, I. J., & Cooper, L. T. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.53 · Cited by 74
(2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.07.057 · Cited by 73
Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
Heart Protection Study Collaborative Group (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.808469 · Cited by 72
KONES, R. J. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s11100 · Cited by 71
Self-citationOtake, H., Shite, J., Shinke, T., Watanabe, S., Tanino, Y., Ogasawara, D., Sawada, T., Hirata, K., & Yokoyama, M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.07.041 · Cited by 71
Eaton, C. B., Galliher, J. M., McBride, P. E., Bonham, A. J., Kappus, J., & Hickner, J. M. (2006) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.19.1.46 · Cited by 71
Predicting the risk of coronary heart disease
Dent, T. H. S. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.019 · Cited by 70
Inflammation reduces HDL protection against primary cardiac risk
Corsetti, J. P., Gansevoort, R. T., Sparks, C. E., & Dullaart, R. P. F. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02287.x · Cited by 68
ACCORD and Risk-Factor Control in Type 2 Diabetes
Nilsson, P. M. (2010) · New England Journal of Medicine · doi:10.1056/nejme1002498 · Cited by 68
Coronary Heart Disease and Prevention in the United States
Brown, J. R., & O’Connor, G. T. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1003880 · Cited by 67
Clinical and Research Applications of Carotid Intima-Media Thickness
Sharma, K., Blaha, M. J., Blumenthal, R. S., & Musunuru, K. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.01.020 · Cited by 66
Lee, K. K., Cipriano, L. E., Owens, D. K., Go, A. S., & Hlatky, M. A. (2010) · Circulation · doi:10.1161/circulationaha.110.947960 · Cited by 65
Rosenson, R. S., Otvos, J. D., & Hsia, J. A. (2009) · Diabetes Care · doi:10.2337/dc08-1681 · Cited by 65
Can dysfunctional HDL explain high coronary artery disease risk in South Asians?
Dodani, S., Kaur, R., Reddy, S. N., Reed, G. L., Navab, M., & George, V. T. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.12.019 · Cited by 64
Simmons, R. K., Unwin, N. C., & Griffin, S. J. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.003 · Cited by 63
Kuklina, E. V., Yoon, P. W., & Keenan, N. L. (2010) · The Annals of Family Medicine · doi:10.1370/afm.1137 · Cited by 62
Tani, S., Watanabe, I., Anazawa, T., Kawamata, H., Tachibana, E., Furukawa, K., Sato, Y., Nagao, K., Kanmatsuse, K., & Kushiro, T. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.05.069 · Cited by 62
Das, U. N. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-130 · Cited by 60
KONES, R. J. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944710391350 · Cited by 60
Self-citationLópez-Jaramillo, P. A., Herrera, E., Garcia, R. G., Camacho, P. A., & Castillo, V. R. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2007.86 · Cited by 60
The role of self-efficacy in cardiovascular disease self-management: a review of effective programs
Katch, H. (2010) · Patient Intelligence · doi:10.2147/pi.s12624 · Cited by 59
The protein cargo of HDL: Implications for vascular wall biology and therapeutics
Heinecke, J. W. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.005 · Cited by 59
Orford, J. L., Sesso, H. D., Stedman, M. R., GAGNON, D. R., Vokonas, P., & Gaziano, J. M. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123317 · Cited by 59
Why We Don't Spend Enough on Public Health
Hemenway, D. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001784 · Cited by 59
KONES, R. J. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s7564 · Cited by 58
Self-citationKnoops, K. T. B., de Groot, C. P. G. M., Kromhout, D., Perrin, A.-É., Moreiras-varela, O., Menotti, A., van Staveren, W. A., Roth, Z., & Brown, G. (2004) · Socio-Environmental Systems Modeling · Cited by 58
Petronio, A. S., Amoroso, G., Limbruno, U., Papini, B., Carlo, M. D., Micheli, A., Ciabatti, N., & Mariani, M. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.10.032 · Cited by 56
Hsia, J. A., Otvos, J. D., Rossouw, J. E., Wu, L., Wassertheil-Smoller, S. W., Hendrix, S. L., Robinson, J. G., Lund, B., & Kuller, L. H. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.170431 · Cited by 55
Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome
Garcia, R. G., Pérez, M., Maas, R., Schwedhelm, E., Böger, R. H., & López-Jaramillo, P. A. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.11.058 · Cited by 54
Dent, T. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.021 · Cited by 54
Currie, C. J., Poole, C., & Conway, P. (2007) · Heart · doi:10.1136/hrt.2007.118794 · Cited by 54
Magnussen, C. G., Thomson, R., Cleland, V., Ukoumunne, O. C., Dwyer, T., & Venn, A. (2011) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2010.246 · Cited by 53
Lipid lowering for primary prevention
Yusuf, S., Lonn, E., & Bosch, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60357-3 · Cited by 52
Pitsavos, C., Panagiotakos, D. B., Tzima, N., Lentzas, Y., Chrysohoou, C., Das, U. N., & Stefanadis, C. (2007) · Angiology · doi:10.1177/0003319707300014 · Cited by 51
Fernández‐Friera, L., García‐Álvarez, A., Bagheriannejad-Esfahani, F., Malick, W. A., Mirelis, J. G., Sawit, S. T., Fuster, V., Sanz, J., Garcia, M. J., & Hermann, L. K. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.08.037 · Cited by 51
Bukkapatnam, R. N., Gabler, N. B., & Lewis, W. R. (2009) · Preventive Cardiology · doi:10.1111/j.1751-7141.2009.00059.x · Cited by 51
Gillum, R. F. (2003) · PubMed · Cited by 50
Wassel, C. L., Barrett-Connor, E. L., & Laughlin, G. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0473 · Cited by 50
Singh, U. S., Devaraj, S., & Jialal, I. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.109207 · Cited by 50
Artinian, N. T., Fletcher, G. F., Mozaffarian, D., Kris-Etherton, P., Van Horn, L., Lichtenstiein, A. H., Kumanyika, S., Kraus, W. E., Fleg, J., Redeker, N. S., et al. (2010) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 50
Adipose “Talks” to Distant Organs to Regulate Insulin Sensitivity and Vascular Function
Zhang, H., & Zhang, C. (2010) · Obesity · doi:10.1038/oby.2010.91 · Cited by 49
Corsetti, J. P., Ryan, D., Rainwater, D. L., Moss, A. J., Zaręba, W., & Sparks, C. E. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.207977 · Cited by 48
Beliefs of blue collar workers regarding coronary risk behaviours
Ritchie, J., Herscovitch, F., & Norfor, J. B. (1994) · Health Education Research · doi:10.1093/her/9.1.95 · Cited by 47
Lipid re-screening: what is the best measure and interval?
Takahashi, O., Glasziou, P., Perera, R., Shimbo, T., Suwa, J., Hiramatsu, S., & Fukui, T. (2009) · Heart · doi:10.1136/hrt.2009.172619 · Cited by 46
Kravitz, B. A., Corrada, M. M., & Kawas, C. H. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02169.x · Cited by 45
Subclinical Atherosclerosis: Evolving Role of Carotid Intima-Media Thickness
Mookadam, F., Moustafa, S., Lester, S. J., & Warsame, T. A. (2010) · Preventive Cardiology · doi:10.1111/j.1751-7141.2010.00072.x · Cited by 45
Choudhry, N. K., Patrick, A. R., Glynn, R. J., & Avorn, J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.059 · Cited by 45
Are You Targeting Non–High-Density Lipoprotein Cholesterol?
Robinson, J. G. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.056 · Cited by 44
Coenzyme Q10 and Statin Myalgia: What is the Evidence?
Mas, E., & Mori, T. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0134-3 · Cited by 43
Köenig, W., & Ridker, P. M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq370 · Cited by 43
Earlier Intervention in the Management of Hypercholesterolemia
Steinberg, D. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.057 · Cited by 42
Management of the Patient with Statin Intolerance
Vandenberg, B., & Robinson, J. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0077-8 · Cited by 42
Drexel, H., Aczél, S., Marte, T., Vonbank, A., & Saely, C. H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.026 · Cited by 42
Coronary atherosclerosis can regress with very intensive statin therapy.
Sipahi, İ., Nicholls, S. J., Tuzcu, E. M., & Nissen, S. E. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.10.937 · Cited by 42
Persell, S. D. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.525 · Cited by 41
Rubin, J., Chang, H., Nasir, K., Blumenthal, R. S., Blaha, M. J., Choi, E., Chang, S., Yoon, Y. E., Chun, E. J., Choi, S., et al. (2011) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.109.929901 · Cited by 41
Carotid intima-media thickness for the practicing lipidologist
Liviakis, L., Pogue, B. W., Paramsothy, P., Bourne, A., & Gill, E. A. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.11.004 · Cited by 40
Takashima, H., Ozaki, Y., Yasukawa, T., Waseda, K., Asai, K., Wakita, Y., Kuroda, Y., Kosaka, T., Kuhara, Y., & Ito, T. (2007) · Circulation Journal · doi:10.1253/circj.71.1678 · Cited by 39
Berry, J. D., Dyer, A. R., Carnethon, M. R., Tian, L., Greenland, P., & Lloyd‐Jones, D. M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.07.079 · Cited by 39
Office-based strategies for the management of obesity.
Rao, G. (2010) · PubMed · Cited by 38
Gooding, H. C., & de Ferranti, S. D. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32833a6e22 · Cited by 38
Efficacy and safety of cholesterol-lowering treatment
Abraha, I., Bonacini, I., & Montedori, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68169-5 · Cited by 38
HDL and Cardiovascular-Disease Risk — Time for a New Approach?
Heinecke, J. W. (2011) · New England Journal of Medicine · doi:10.1056/nejme1012520 · Cited by 38
Johnson, K. M., & Dowe, D. A. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.2487 · Cited by 38
Optimal Cardiovascular Prevention Strategies for the 21st Century
Capewell, S., & Lloyd‐Jones, D. M. (2010) · JAMA · doi:10.1001/jama.2010.1641 · Cited by 37
Serial quantitative coronary angiography and coronary events
Mack, W. J., Xiang, M., Selzer, R. H., & Hodis, H. N. (2000) · American Heart Journal · doi:10.1067/mhj.2000.105702 · Cited by 37
Ishii, H., Toriyama, T., Aoyama, T., Takahashi, H., Amano, T., Hayashi, M., Tanaka, M., Kawamura, Y., Yasuda, Y., Yuzawa, Y., et al. (2009) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.889915 · Cited by 37
Redefining Normal Low-Density Lipoprotein Cholesterol
Forrester, J. S. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.11.090 · Cited by 36
Targeting the Anti-Inflammatory Effects of High-Density Lipoprotein
Ansell, B. J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.08.006 · Cited by 36
Rumberger, J. A. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s7457 · Cited by 36
Corsetti, J. P., Zaręba, W., Moss, A. J., Rainwater, D. L., & Sparks, C. E. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.09.012 · Cited by 36
Primary Prevention of Cardiovascular Disease: Time to Get More or Less Personal?
Hingorani, A. D., & Psaty, B. M. (2009) · JAMA · doi:10.1001/jama.2009.1698 · Cited by 36
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence
Brown, B. G., Zhao, X.-Q., & Cheung, M. C. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.02.004 · Cited by 36
Wald, N., & Wald, D. S. (2009) · Postgraduate Medical Journal · doi:10.1136/hrt.2009.186429 · Cited by 36
Can the polypill save the world from heart disease?
Cannon, C. P. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60652-8 · Cited by 35
Screening Asymptomatic Subjects for Subclinical Atherosclerosis
Lauer, M. S. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.059 · Cited by 34
Cardiac risk stratification: Role of the coronary calcium score
Sharma, R. K. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8753 · Cited by 34
Enhanced Cellular Uptake of Remnant High-Density Lipoprotein Particles
Xiao, C., Watanabe, T., Zhang, Y., Trigatti, B. L., Szeto, L., Connelly, P. W., Marcovina, S. M., Vaisar, T., Heinecke, J. W., & Lewis, G. F. (2008) · Circulation Research · doi:10.1161/circresaha.108.178756 · Cited by 33
Predicting Cardiovascular Risk: So What Do We Do Now?
Lloyd‐Jones, D. M., & Tian, L. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.13.1342 · Cited by 33
A Zero Coronary Artery Calcium Score
Hecht, H. S. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.064 · Cited by 33
O’Gorman, C. S., Conwell, L. S., & O‘Neill, M. F. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s7356 · Cited by 32
Evaluation and management of hyperlipidemia in children and adolescents
Iughetti, L., Bruzzi, P., & Predieri, B. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32833ab869 · Cited by 32
A polypill for secondary prevention: time to move from intellectual debate to action
Fuster, V., & Sanz, G. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0858 · Cited by 32
Carotid Intima-Media Thickness, Plaques, and Cardiovascular Disease Risk
Stein, J. H., & Johnson, H. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.11.073 · Cited by 32
Utilization of lipid lowering medications among adults in the United States 1999–2006
Li, M., Ong, K. L., Tse, H., & Cheung, B. M. Y. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.001 · Cited by 31
Sacker, A., Head, J. A., & Bartley, M. (2008) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181642ef5 · Cited by 30
Ghandehari, H., Kamal‐Bahl, S. J., & Wong, N. D. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.10.046 · Cited by 29
Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
Hermans, M. P., & Fruchart, J. (2010) · Clinical Lipidology · doi:10.2217/clp.10.65 · Cited by 28
The Prevention Of Cardiovascular Disease: Have We Really Made Progress?
Pearson, T. A. (2007) · Health Affairs · doi:10.1377/hlthaff.26.1.49 · Cited by 28
Diet as preventive medicine in cardiology
de Lorgeril, M., & Salen, P. (2000) · Current Opinion in Cardiology · doi:10.1097/00001573-200009000-00009 · Cited by 28
Arteriogenesis requires toll-like receptor 2 and 4 expression in bone-marrow derived cells
de Groot, D., Hoefer, I. E., Grundmann, S., Schoneveld, A. H., Haverslag, R. T., van Keulen, J. K., Bot, P. T. G., Timmers, L., Piek, J. J., Pasterkamp, G., et al. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.08.006 · Cited by 28
Strategies of prevention: the individual and the population
Rose, G. (2005) · doi:10.1093/acprof:oso/9780198525738.003.0037 · Cited by 28
Primary Prevention of Coronary Artery Disease
DOMANSKI, M. J. (2007) · New England Journal of Medicine · doi:10.1056/nejme078183 · Cited by 27
Shifting views on lipid lowering therapy
Krumholz, H. M., & Hayward, R. A. (2010) · BMJ · doi:10.1136/bmj.c3531 · Cited by 26
Inflammation in Atherosclerosis
Lauterbach, M., Labzin, L. I., & Latz, E. (2017) · Wiley-VCH eBooks · doi:10.1002/9783527692156.ch49 · Cited by 26
Efficacy and safety of intensive statin therapy in the elderly.
Maroo, B. P., Lavie, C. J., & Milani, R. V. (2008) · PubMed · Cited by 25
Statin Therapy and the Elderly: SAGE Advice?
Gotto, A. M. (2007) · Circulation · doi:10.1161/circulationaha.106.678300 · Cited by 25
Recommendations of the U.S. Preventive Services Task Force.
Dickey, L. L. (1997) · PubMed · Cited by 25
Statins and the Reduction of Sudden Cardiac Death
Beri, A., Contractor, T. A., Khasnis, A. A., & Thakur, R. K. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11536690-000000000-00000 · Cited by 24
Rizzo, M., Corrado, E., Coppola, G., Muratori, I. M., Mezzani, A., Novo, G., & Novo, S. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.01955.x · Cited by 24
Xu, L., Jiang, C. Q., Lam, T. H., Lin, J. M., Yue, X. J., Cheng, K. K., Liu, B., Jin, Y. L., Zhang, W. S., & Thomas, G. N. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03760.x · Cited by 24
Lebenthal, Y., Horvath, A., Dziechciarz, P., Szajewska, H., & Shamir, R. (2010) · Archives of Disease in Childhood · doi:10.1136/adc.2008.157024 · Cited by 24
PANEL ON UNDERSTANDING DIVERGENT TRENDS IN LONGEVITY IN HIGH-INCOME COUNTRIES
Crimmins, E. M., Preston, S. H., & Cohen, B. (2011) · Cited by 23
See, R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.10.1055 · Cited by 23
Nichols, G. A., Nag, S. S., & Chan, W. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.04.037 · Cited by 23
Howard, W. J. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79113-3 · Cited by 23
Howard, W. J. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79125-x · Cited by 23
Statin Therapy in Young Adults
Pletcher, M. J., & Hulley, S. B. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.018 · Cited by 22
Is HDL function as important as HDL quantity in the coronary artery disease risk assessment?
Dodani, S., Grice, D. G., & Joshi, S. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.02.001 · Cited by 22
Getz, G. S., & Reardon, C. A. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.210583 · Cited by 22
Hyperlipidaemia in Paediatric Patients: The Role of Lipid-Lowering Therapy in Clinical Practice
Wierzbicki, A. S., & Viljoen, A. (2010) · Drug Safety · doi:10.2165/11319490-000000000-00000 · Cited by 20
Michos, E. D., Long, S., Blaha, M. J., & Blumenthal, R. S. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s8101 · Cited by 20
Obstacles to cardiovascular prevention in general practice
MUYLDER, R. D., Lorant, V., Paulus, D., Nackers, F., Jeanjean, M., & Boland, B. B. (2004) · Acta Cardiologica · doi:10.2143/ac.59.2.2005165 · Cited by 20
Challenges and strategies to improve patient health literacy and competencies
Bosworth, H. B. (2010) · Patient Intelligence · doi:10.2147/pi.s9491 · Cited by 18
Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients
Wenger, N. K., & Lewis, S. J. (2010) · Current Gerontology and Geriatrics Research · doi:10.1155/2010/915296 · Cited by 18
Nakamura, H. (2007) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2007.02.003 · Cited by 18
Costanzo, P., Filardi, P. P., & Vassallo, E. (2011) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.06.089 · Cited by 18
Kaul, P., & Douglas, P. S. (2009) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.109.850263 · Cited by 18
Nambi, V., & Ballantyne, C. M. (2009) · Circulation · doi:10.1161/circulationaha.108.830281 · Cited by 17
Shimabukuro, M., Higa, M., Tanaka, H., Shimabukuro, T., Yamakawa, K., & Masuzaki, H. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03240.x · Cited by 16
Brindis, R., & Spertus, J. A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.004 · Cited by 16
Lipid lowering goals: back to nature?
Hochholzer, W., & Giugliano, R. P. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944710368206 · Cited by 16
Negi, S., & Ballantyne, C. M. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.008 · Cited by 16
Weber, M. W., Bhatt, D. L., Brennan, D. M., Hankey, G. J., Steinhubl, S. R., Johnston, S. C., Montalescot, G., Mak, K.-H., Fox, K. A. A., Easton, D., et al. (2011) · Heart · doi:10.1136/hrt.2010.210419 · Cited by 16
Placing the cardiovascular risk of childhood obesity in perspective
Ayer, J. G., & Steinbeck, K. S. (2010) · International Journal of Obesity · doi:10.1038/ijo.2009.183 · Cited by 15
Commentary: Obesity claims and controversies
Stevens, J., McClain, J. E., & Truesdale, K. P. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyi258 · Cited by 15
Berenson, G. S. (2009) · Preventive Cardiology · doi:10.1111/j.1751-7141.2009.00049.x · Cited by 15
Dullaart, R. P. F. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.209544 · Cited by 14
A Double Take on Serial Measurement of Coronary Artery Calcification
O’Malley, P. G. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.418 · Cited by 14
Bu, D.-X., & Lichtman, A. H. (2010) · Circulation · doi:10.1161/circulationaha.110.991059 · Cited by 14
Toth, P. P. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.05.012 · Cited by 14
Is intensive LDL-cholesterol lowering beneficial and safe?
Cheung, B. M. Y., & Lam, K. S. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61545-0 · Cited by 13
Torcetrapib And Atherosclerosis: What Happened And Where Do We Go From Here?
Toth, P. P. (2007) · Future Lipidology · doi:10.2217/17460875.2.3.277 · Cited by 13
Screening for heart disease: C-reactive protein versus coronary artery calcium
Patel, A., & Budoff, M. J. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.166 · Cited by 13
Davidson, M. H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.025 · Cited by 13
Ridker, P. M. (2011) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.111.965053 · Cited by 13
Adipose inflammation: cause or consequence of obesity-related insulin resistance
Xu, H. (2008) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s4180 · Cited by 12
Cardiovascular Risk in Young Persons: Secondary or Primordial Prevention?
Berenson, G. S., & Srinivasan, S. R. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00012 · Cited by 12
Zieman, S. J., & Ouyang, P. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-8-201004200-00011 · Cited by 11
Biomarkers for Coronary Heart Disease Clinical Risk Prediction: A Critical Appraisal
Wilkins, J. T., & Lloyd‐Jones, D. M. (2010) · Preventive Cardiology · doi:10.1111/j.1751-7141.2010.00081.x · Cited by 10
Crouse, J. R., Bots, M. L., Evans, G. W., Palmer, M. K., O’Leary, D. H., Grobbee, D. E., & Raichlen, J. S. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283359c38 · Cited by 10
Diabetic dyslipidemia: extending the target beyond LDL cholesterol
Nicholls, S. J., Lundman, P., & Tardif, J. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000368195.09485.17 · Cited by 10
de Lemos, J. A., & Rohatgi, A. K. (2010) · Circulation · doi:10.1161/circulationaha.110.953463 · Cited by 10
The role of coronary artery calcification score in clinical practice
Piers, L. H., Salachova, F., Slart, R. H. J. A., Vliegenthart, R., Dikkers, R., Hospers, F. A. P., Bouma, H. R., Zeebregts, C. J., Willems, T. P., Oudkerk, M., et al. (2008) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-8-38 · Cited by 10
Brown, R., & Rader, D. J. (2008) · Circulation Research · doi:10.1161/circresaha.108.180638 · Cited by 10
KONES, R. J. (2010) · Nutrition in Clinical Practice · doi:10.1177/0884533610380614 · Cited by 9
Self-citationTargeting Residual Risk: The Rationale for the Use of Non-HDL Cholesterol
Alla, V. M., Kaushik, M., & Mooss, A. N. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181d7e3a8 · Cited by 9
Considerable uncertainty remains in the evidence for primary prevention of cardiovascular disease
Heneghan, C. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000017 · Cited by 9
Sacks, F. M., Tonkin, A. M., & Craven, T. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00773-0 · Cited by 9
Improving Lipid Goal Attainment
Gotto, A. M. (2009) · Circulation · doi:10.1161/circulationaha.109.871913 · Cited by 8
Innate immunity meets arteriogenesis: The versatility of toll-like receptors
Monaco, C. G. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.015 · Cited by 7
Not All Body Fat Weighs Equally in the Acceleration of Coronary Artery Disease
Berman, D. S., Cheng, V., & Dey, D. (2010) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2010.08.002 · Cited by 6
Nambi, V., & Ballantyne, C. M. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0071-8 · Cited by 6
Dayspring, T. D., Dall, & Abuhajir (2010) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s14825 · Cited by 6
Núñez-Cortés, J. M., Pedro‐Botet, J., Salas, X. P., Mijares, A. H., Carey, V. J., Hermans, M. P., Sacks, F. M., & Fruchart, J. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2010.10.004 · Cited by 6
Editor's Correspondence: COMMENTS AND OPINIONS
Pippin, J. J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.402 · Cited by 5
Patients’ attention to and understanding of adverse drug reaction warnings
McNeal, Colbert, C. Y., Cable, Mirkes, Lubowinski, & Myers (2010) · Patient Intelligence · doi:10.2147/pi.s9569 · Cited by 5
The Effect of Weight Loss on C-Reactive Protein: A Systematic Review
Selvin, E. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.1.31 · Cited by 5
DeMazumder, D., Hasan, R. K., Blumenthal, R. S., Michos, E. D., & Jones, S. R. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.015 · Cited by 5
Núñez-Cortés, J. M., Pedro‐Botet, J., Salas, X. P., Mijares, A. H., Carey, V. J., Hermans, M. P., Sacks, F. M., & Fruchart, J. (2011) · Endocrinología y Nutrición (English Edition) · doi:10.1016/s2173-5093(11)70035-6 · Cited by 5
Starting early to control all risk factors in order to prevent coronary heart disease
McGill, H. C., & McMahan, C. A. (2010) · Clinical Lipidology · doi:10.2217/clp.09.82 · Cited by 5
The Cost-Effectiveness of Rosuvastatin Therapy
Hlatky, M. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.051 · Cited by 5
Hochdosierte Statintherapie für kardiovaskuläre Risikopatienten
Saely, C. H., Drexel, H., & Huber, K. (2010) · Herz · doi:10.1007/s00059-010-3381-8 · Cited by 4
Wilkins, J. T., & Lloyd‐Jones, D. M. (2009) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-009-0023-x · Cited by 4
Prenatal nutritional influences on obesity risk in offspring
Sloboda, D. M., & Vickers (2010) · Nutrition and Dietary Supplements · doi:10.2147/nds.s8555 · Cited by 4
COSEHC global vascular risk management quality improvement program: rationale and design
Ferrario, C. M., Moore, M. A., Bestermann, W., Colby, C., Exuzides, A., Simmons, D., & Panjabi, S. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s13746 · Cited by 4
White, S. J. (2011) · Patient Intelligence · doi:10.2147/pi.s12425 · Cited by 4
Coronary Artery Calcification, an Improvement in Risk Classification
Duprez, D. A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.027 · Cited by 4
Cited by
High-Sensitivity C-Reactive Protein and Cardiovascular Disease
Yousuf, O., Mohanty, B. D., Martin, S. S., Joshi, P. H., Blaha, M. J., Nasir, K., Blumenthal, R. S., & Budoff, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.016 · Cited by 494
Kandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Ž., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/8732360 · Cited by 136
Boelstler, A. M., Rowland, R., Theoret, J., Takla, R. B., Szpunar, S., Patel, S. P., Lowry, A. M., & Pena, M. E. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.10.014 · Cited by 23
Metadata
- Authors
- Kones, R.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-06
- Volume
- 5
- Pages
- 325
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2102337961
- Cited by
- 259
- References
- 608
- FWCI
- 28.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.